Document Detail


Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition.
MedLine Citation:
PMID:  19363707     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We summarize our experience and propose methods for early diagnosis and treatment of intravascular large B cell lymphoma (IVL). A total of 16 patients with IVL between 1994 and 2007 were included and analyzed in this study. Predicted survival durations were short until September 2003. However, there have been marked improvement since the introduction of rituximab, and all patients responded to treatment and survived for more than 1 year following diagnosis of IVL. We propose an early clinical diagnostic strategy for starting treatment for IVL patients with quite poor performance status (PS) and in whom time is a limiting factor: (1) age >40 years, (2) fever above 38 degrees C with poor PS (ECOG 2-4), (3) lactate dehydrogenase (LDH) more than twice the upper limit of the normal level and/or sIL2R >5,000 IU/ml in serum, (4) worsening PS and/or elevation of serum LDH on a daily basis, and (5) confirmation of pathological lymphoid cells in peripheral blood or bone marrow smear and/or flow cytometry. Although accurate pathological diagnosis is quite important, time is a limiting factor for most of IVL patients. In such cases, we can start chemotherapy based on early clinical diagnostic strategy with high sensitivity and obtain good clinical outcome.
Authors:
Yasufumi Masaki; Lingli Dong; Akio Nakajima; Haruka Iwao; Miyuki Miki; Nozomu Kurose; Eriko Kinoshita; Takayuki Nojima; Toshioki Sawaki; Takafumi Kawanami; Masao Tanaka; Kumiko Shimoyama; Changi Kim; Masaaki Fukutoku; Hiroshi Kawabata; Toshihiro Fukushima; Yuko Hirose; Tomoo Takiguchi; Susumu Konda; Susumu Sugai; Hisanori Umehara
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-14
Journal Detail:
Title:  International journal of hematology     Volume:  89     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-02     Completed Date:  2009-09-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  600-10     Citation Subset:  IM    
Affiliation:
Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Ishikawa, Japan. yasum@kanazawa-med.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Early Detection of Cancer*
Female
Humans
Lymphoma, B-Cell / diagnosis*,  drug therapy
Male
Middle Aged
Retrospective Studies
Vascular Neoplasms / diagnosis*,  drug therapy
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic value of myocardial perfusion and ventricular function in a Japanese multicenter cohort s...
Next Document:  Modification of TGF-beta1 signaling pathway during NB4 cells differentiation by all-trans retinoid a...